NovoCure
NVCR
85 hedge funds and large institutions have $567M invested in NovoCure in 2017 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 35 increasing their positions, 15 reducing their positions, and 10 closing their positions.
925% more call options, than puts
Call options by funds: $17.7M | Put options by funds: $1.73M
230% more capital invested
Capital invested by funds: $172M → $567M (+$395M)
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
133% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 15
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
20% more funds holding
Funds holding: 71 → 85 (+14)
13.12% more ownership
Funds ownership: 24.08% → 37.2% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$63.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$15.7M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$4.71M |
| 2 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
-$4.22M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.74M |
| 4 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$1.11M |
| 5 |
HCM
Highline Capital Management
New York
|
-$773K |
NVCR Hedge Fund Activity: Q2 2017 in Review
85 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2017, worth a combined $567M — up 230% from $172M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NVCR positions and 10 closed out — a net gain of 14 holders — while 35 added to existing stakes and 15 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $63.4M. The largest seller was Peregrine Capital Management, cutting an estimated $4.71M.
- 85 institutional investors held NovoCure (NVCR) as of Q2 2017, up from 71 in Q1 2017.
- Funds reported $567M of NovoCure stock for Q2 2017, up 230% quarter-over-quarter.
- 24 funds opened new NovoCure positions in Q2 2017 and 10 closed out, a net change of +14 holders.
- The largest NovoCure buyer in Q2 2017 was Goldman Sachs, an estimated $63.4M added.
- The largest NovoCure seller in Q2 2017 was Peregrine Capital Management, an estimated $4.71M sold.
Based on aggregated 13F filings for Q2 2017.